Gemtuzumab Ozogamicin represents a important breakthrough in the treatment of aggressive leukemic leukemia, mainly relapsed myeloblastic cancer (AML). The conjugate pairs a targeted immunoglobulin directed at the https://www.targetmol.com/compound/gemtuzumab